[b]Keryx Biopharmaceuticals...
Published (2010-01-05 08:51:09)
[b]Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of Hyperphosphatemia Milestone Marks Attainment of SPA Agreements for Both of Keryx's Phase 3 Drug Candidates, Zerenex and Perifosine[/b] NEW YORK, Jan. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and...